Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Phase 2

Terminated

Conditions: Colon Cancer
Adenocarcinoma

Interventions: Drug: XELOX
Drug: XELIRI
Drug: Bevacizumab

First Posted Date: 2005-08-05

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 65

Registration Number: NCT00127036

Locations: 🇺🇸
St. Joseph's Candler Health System, Savannah, Georgia, United States
🇺🇸
Bay Area Oncology, Tampa, Florida, United States
🇺🇸
Fawcett Memorial Hospital, Port Charlotte, Florida, United States

and more 9 locations

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Methotrexate

First Posted Date: 2005-07-21

Last Posted Date: 2013-12-24

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 164

Registration Number: NCT00121134

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2005-07-21

Last Posted Date: 2011-04-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 109

Registration Number: NCT00121836

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: Oxaliplatin
Drug: bevacizumab

First Posted Date: 2005-07-12

Last Posted Date: 2011-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 435

Registration Number: NCT00118755

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-06-30

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00116506

Locations: 🇺🇸
Massachusett General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States